PHARMACOEPIDEMIOLOGICAL ASPECTS OF PRESCRIPTION OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN A HOSPITAL CONDITION

Diabetes mellitus type 2 (type 2 diabetes) is generally recognized as one of the non-infectious pandemics of modern humanity. The results of international studies indicate that more than 500 million people suffer from this disease throughout the planet; Unfortunately, the current trend tends to increase the number of new cases of newly diagnosed type 2 diabetes: in the next 30 years, the proportion of patients with this disease in the general population may double again. Aim. To study the structure and frequency of prescription of sodium-glucose cotransporter type 2 inhibitors (NGLT-2 inhibitors) in patients with type 2 diabetes mellitus (DM) in the endocrinology department of one of the hospitals in Kursk for the period July - December 2023. Materials and methods. Using a continuous sampling method, the medical records of 297 patients with type 2 diabetes who were under observation in the endocrinology department of one of the hospitals in Kursk from July to December 2023 were analyzed. Results. The total number of prescriptions for oral glycemic drugs was 583, of which 121 (20.8%) were in the group of SGLT-2 inhibitors. 13.7% accounted for dapagliflozin, 6.2% for empagliflozin, 0.9% for ipragliflozin (of the total number of prescriptions, respectively). The intragroup structure of prescriptions for this class of drugs was represented by empagliflozin (29.8%), dapagliflozin (66.1%), and ipragliflozin (4.1%, respectively). Canagliflozin and ertugliflozin were not used in hospital settings. The frequency of use of these drugs among inpatients (n = 297) was: 26.9% for dapagliflozin, 12.1% for empagliflozin and 1.7% for ipragliflozin, respectively. Conclusion. Currently, the use of SGLT-2 inhibitors is recommended by both national and international guidelines and protocols for the management of patients with type 2 diabetes; therefore, they (in particular, empagliflozin and dapagliflozin) occupy one of the leading positions in real clinical practice - in general, and in hospital settings - in particular.

1. IDF diabetes Atlas: Global estimates of undiagnosed diabetes in adults for 2021 / K. Ogurtsova, L. Guariguata, NC Barengo [et al.] // Diabetes Research and Clinical Practice. – 2022. – Vol. 183. – P. 109118. – DOI 10.1016/j.diabres.2021.109118. – EDN VGLRUA.

2. Algorithms for specialized medical care for patients with diabetes. Edited by I.I. Dedova, M.V. Shestakova, A.Yu. Mayorova. 10th issue / I. I. Dedov, M. V. Shestakova, A. Yu. Mayorov [etc.] // Diabetes mellitus. – 2021. – T. 24, No. S1. – P. 1-148. – DOI 10.14341/DM12802. – EDN ISOZCM.

3. Fitchett, DH Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes / DH Fitchett, JA Udell, SE Inzucchi // European Journal of Heart Failure. – 2017. – Vol. 19, No. 1. – P. 43-53. – DOI 10.1002/ejhf.633. – EDN HGNEMT.

4. Sukhareva, O. Yu. Updating the positions of gliflozins in treatment algorithms for patients with type 2 diabetes mellitus and chronic kidney disease: new pathogenetic mechanisms and data from subanalyses of large randomized controlled studies / O. Yu. Sukharev a, Z. T. Zuraeva, M. Sh. Shamkhalova // Diabetes. – 2021. – T. 24, No. 6. – P. 553-564. – DOI 10.14341/DM12864. – EDN RGSCSX.

5. Type 2 diabetes mellitus in adults. Clinical recommendations / Russian Association of Endocrinologists // M., 2022. – 251 p.

6. Maloletkina, E. S. Advantages of inhibition of sodium-glucose cotransporter type 1 in everyday clinical practice / E. S. Maloletkina, V. V. Fadeev // Breast cancer. – 2022. – No. 1. – P. 20-25. – EDN VOEDHY.

7. Characteristics of purchases of hypoglycemic drugs in the commercial sector in dynamics for 2016-2020 / D. V. Kurkin, E. V. Makarova, I. S. Krysanov [et al.] // Problems of endocrinology. – 2023. – T. 69, No. 4. – P. 50-60. – DOI 10.14341/probl13200. – EDN QXCMMY.

8. Andriashvili, T. M. Review of pharmacy sales of hypoglycemic drugs / T. M. Andriashvili, A. A. Sokolova // XXVI Regional Conference of Young Scientists and Researchers of the Volgograd Region: Collection of articles, Volgograd, November 19, 2021 / Volgograd State medical University. – Volgograd: VolSMU, 2023. – P. 440-443. – EDN EJFVKO.

9. ElSayed NA, Aleppo G, Aroda VR, et al. Summary of Revisions: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S5-S9. doi:10.2337/dc23-Srev.

10. Algorithms for specialized medical care for patients with diabetes mellitus / Edited by I.I. Dedova, M.V. Shestakova, A.Yu. Mayorova. 11th issue / I. I. Dedov, M. V. Shestakova, A. Yu. Mayorov [etc.] // Diabetes mellitus. – 2023. – T. 26, No. S2. – P. 1-157. – DOI 10.14341/DM13042. – EDN DCKLCI.

11. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC), European Heart Journal, Volume 44, Issue 39 , 14 October 2023, Pages 4043–4140, https://doi.org/10.1093/eurheartj/ehad192.